407 related articles for article (PubMed ID: 33120429)
21. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome.
Herrera AF; Ahn KW; Litovich C; Chen Y; Assal A; Bashir Q; Bayer RL; Coleman M; DeFilipp Z; Farhadfar N; Greenwood M; Hahn T; Horwitz M; Jacobson C; Jaglowski S; Lachance S; Langston A; Mattar B; Maziarz RT; McGuirk J; Mian MAH; Nathan S; Phillips A; Rakszawski K; Sengeloev H; Shenoy S; Stuart R; Sauter CS; Kharfan-Dabaja MA; Hamadani M
Blood Adv; 2021 Sep; 5(18):3528-3539. PubMed ID: 34496026
[TBL] [Abstract][Full Text] [Related]
22. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
González-Barca E; Boumendil A; Blaise D; Trněný M; Masszi T; Finel H; Michieli MG; Bittenbring JT; Gritti G; Snowden JA; Bishton M; Bruno B; de Villambrosia SG; Janikova A; Leleu X; Anagnostopoulos A; Poiré X; Crysandt M; Özkurt ZN; Vandenberghe E; Itälä-Remes M; Cahn JY; Jantunen E; Schroyens W; Maertens J; Esquirol A; Dreger P; Montoto S; Sureda A
Bone Marrow Transplant; 2020 Feb; 55(2):393-399. PubMed ID: 31541205
[TBL] [Abstract][Full Text] [Related]
23. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
24. Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL.
Jeyakumar N; Smith M
Front Immunol; 2022; 13():887866. PubMed ID: 35663947
[TBL] [Abstract][Full Text] [Related]
25. Matched unrelated donor allogeneic transplantation provides comparable long-term outcome to HLA-identical sibling transplantation in relapsed diffuse large B-cell lymphoma.
Avivi I; Canals C; Vernant JP; Wulf G; Nagler A; Hermine O; Petersen E; Yakoub-Agha I; Craddock C; Schattenberg A; Niederwieser D; Thomson K; Blaise D; Attal M; Pfreundschuh M; Passweg J; Russell N; Dreger P; Sureda A;
Bone Marrow Transplant; 2014 May; 49(5):671-8. PubMed ID: 24510071
[TBL] [Abstract][Full Text] [Related]
26. Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era.
Hunter BD; Herr M; Meacham PJ; Barlaskar F; Evans AG; Burack WR; Liesveld JL; Becker MW; Milner LA; Constine LS; Dhakal S; Barr PM; Friedberg JW; Casulo C
Clin Lymphoma Myeloma Leuk; 2017 Mar; 17(3):145-151. PubMed ID: 27998707
[TBL] [Abstract][Full Text] [Related]
27. C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional "hits" and outcomes with subsequent therapy.
Epperla N; Maddocks KJ; Salhab M; Chavez JC; Reddy N; Karmali R; Umyarova E; Bachanova V; Costa C; Glenn M; Calzada O; Xavier AC; Zhou Z; Hossain NM; Hernandez-Ilizaliturri FJ; Al-Mansour Z; Barta SK; Chhabra S; Lansigan F; Mehta A; Jaglal MV; Evens AM; Flowers CR; Cohen JB; Fenske TS; Hamadani M; Costa LJ
Cancer; 2017 Nov; 123(22):4411-4418. PubMed ID: 28749548
[TBL] [Abstract][Full Text] [Related]
28. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy.
Bal S; Costa LJ; Sauter C; Litovich C; Hamadani M
Transplant Cell Ther; 2021 Jan; 27(1):55.e1-55.e7. PubMed ID: 32949754
[TBL] [Abstract][Full Text] [Related]
30. The value of complete remission according to positron emission tomography prior to autologous stem cell transplantation in lymphoma: a population-based study showing improved outcome.
Noring K; Carlsten M; Sonnevi K; Wahlin BE
BMC Cancer; 2021 May; 21(1):500. PubMed ID: 33947353
[TBL] [Abstract][Full Text] [Related]
31. Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Epperla N; Fenske TS; Lazarus HM; Hamadani M
Bone Marrow Transplant; 2015 Nov; 50(11):1393-404. PubMed ID: 26281033
[TBL] [Abstract][Full Text] [Related]
32. Surveillance Imaging after Autologous Hematopoietic Cell Transplantation Predicts Survival in Patients with Diffuse Large B Cell Lymphoma.
Savani M; Gencturk M; Shanley R; Cayci Z; Wilke C; Warlick ED; He F; Janakiram M; Weisdorf DJ; Brunstein CG; Bachanova V
Biol Blood Marrow Transplant; 2020 Feb; 26(2):272-277. PubMed ID: 31669174
[TBL] [Abstract][Full Text] [Related]
33. Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors.
Klyuchnikov E; Bacher U; Kröger NM; Hari PN; Ahn KW; Carreras J; Bachanova V; Bashey A; Cohen JB; D'Souza A; Freytes CO; Gale RP; Ganguly S; Hertzberg MS; Holmberg LA; Kharfan-Dabaja MA; Klein A; Ku GH; Laport GG; Lazarus HM; Miller AM; Mussetti A; Olsson RF; Slavin S; Usmani SZ; Vij R; Wood WA; Maloney DG; Sureda AM; Smith SM; Hamadani M
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2091-2099. PubMed ID: 26253007
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study.
Ansell SM; Minnema MC; Johnson P; Timmerman JM; Armand P; Shipp MA; Rodig SJ; Ligon AH; Roemer MGM; Reddy N; Cohen JB; Assouline S; Poon M; Sharma M; Kato K; Samakoglu S; Sumbul A; Grigg A
J Clin Oncol; 2019 Feb; 37(6):481-489. PubMed ID: 30620669
[TBL] [Abstract][Full Text] [Related]
35. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience.
Rezvani AR; Norasetthada L; Gooley T; Sorror M; Bouvier ME; Sahebi F; Agura E; Chauncey T; Maziarz RT; Maris M; Shizuru J; Bruno B; Bredeson C; Lange T; Yeager A; Sandmaier BM; Storb RF; Maloney DG
Br J Haematol; 2008 Nov; 143(3):395-403. PubMed ID: 18759762
[TBL] [Abstract][Full Text] [Related]
36. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
van Imhoff GW; McMillan A; Matasar MJ; Radford J; Ardeshna KM; Kuliczkowski K; Kim W; Hong X; Goerloev JS; Davies A; Barrigón MDC; Ogura M; Leppä S; Fennessy M; Liao Q; van der Holt B; Lisby S; Hagenbeek A
J Clin Oncol; 2017 Feb; 35(5):544-551. PubMed ID: 28029326
[TBL] [Abstract][Full Text] [Related]
37. CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma.
Sauter CS; Senechal B; Rivière I; Ni A; Bernal Y; Wang X; Purdon T; Hall M; Singh AN; Szenes VZ; Yoo S; Dogan A; Wang Y; Moskowitz CH; Giralt S; Matasar MJ; Perales MA; Curran KJ; Park J; Sadelain M; Brentjens RJ
Blood; 2019 Aug; 134(7):626-635. PubMed ID: 31262783
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of
Ying Z; Mi L; Zhou N; Wang X; Yang Z; Song Y; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Zhang C; Liu W; Deng L; Zhu J
Chin J Cancer Res; 2019 Feb; 31(1):162-170. PubMed ID: 30996574
[TBL] [Abstract][Full Text] [Related]
39. Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma.
Wang T; Gao L; Wang Y; Zhu W; Xu L; Wang Y; Yue W; Tang G; Chen L; Chen J; Zhang W; Yu X; Feng D; Yang J
Immunotherapy; 2020 Sep; 12(13):997-1006. PubMed ID: 32752910
[No Abstract] [Full Text] [Related]
40. Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy.
Guidetti A; Dodero A; Lorenzoni A; Pizzamiglio S; Argiroffi G; Chiappella A; Bagnoli F; Marasco V; Carniti C; Monfrini C; Seregni E; Pennisi M; Verderio P; Alessi A; Corradini P
Cancer; 2023 Jan; 129(2):255-263. PubMed ID: 36385707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
